Actavis-Allergan: Anatomy of a $66B Deal

The transcript discusses the merger between Allergan and Activist, highlighting the creation of a top ten pharmaceutical company. Jeff McCracken from Bloomberg provides insights into the merger's financial aspects, market reactions, and strategic decisions. The conversation also touches on R&D spending, company reputations, and the dynamics of the pharmaceutical industry, including past and potential partnerships.

What strategies did Allergan employ to counter Valeant's influence?

What questions arise regarding the future of R&D spending after the merger?